Blood Cancer Talks

In this episode, we discuss the techniques to assess measurable residual disease (MRD) in AML, clinical implications of MRD results, and future directions on MRD-guided patient management.

Show Notes

2021 European LeukemiaNET MRD Working Party Consensus Guidelines:

Pre-MEASURE Study ASCO 2022:

What is Blood Cancer Talks?

This is a podcast on latest advances in the understanding and management of blood cancers. Here, we will bring a wide range of experts within hematologic malignancies to discuss various topics in depth.
Host: Raj Chakraborty, MD from Columbia University, New York, Ashwin Kishtagari, MD, from Vanderbilt University, Nashville, and Edward Cliff, MD, from Harvard University, Boston
Tweet your suggestions and feedback to @rajshekharucms @AshKishtagari @Eddie_Cliff @BloodCancerTalk